Palatin’s PL8177 shows therapuetic efficacy in inflammatory bowel disease

Palatin announced that Frontiers in Immunology published a manuscript summarizing data demonstrating oral PL8177 provides therapeutic effects in inflammatory bowel disease and pharmacokinetic data from a clinical study showing PL8177 remains restricted to the gut. Key findings included maintenance of intact colon structure and barrier, reduced immune cell infiltration, and increased enterocytes with PL8177 treatment. Compared with vehicle, PL8177 treated colon samples show positive effects on immune marker genes and diverse, well known immune-related pathways. Palatin is conducting a Phase 2 clinical study of PL8177, with once daily oral dosing in adult patients with active UC. The PL8177-205 interim assessment is expected to occur in the first half of calendar year 2023, with final topline data anticipated in the second half of calendar year 2023.